Antiverse, a Cardiff, UK-based biotechnology company developing a computational antibody drug discovery platform, raised $3M in funding.
Backers included InnoSpark, AngelHub, Kadmos Capital and Tomorrow Scale, as well as existing investors, Tensor Ventures, Deep Science Ventures, Ed Parkinson and Development Bank of Wales (DBW).
The company intends to use the funds to develop in-house the antibodies showing the highest affinity blocking function, making them ideal starting points as therapeutic assets.
Founded in 2017 and led by CEO Murat Tunaboylu, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses sequencing and AI to curate diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.
The company also announced the identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.
FinSMEs